Presented in abstract form at the Veterinary Cancer Society Annual Conference, Albuquerque, New Mexico, November 2011.
Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999–2012)†
Version of Record online: 31 MAY 2013
© 2013 Blackwell Publishing Ltd
Veterinary and Comparative Oncology
Volume 13, Issue 3, pages 267–280, September 2015
How to Cite
Lejeune, A., Skorupski, K., Frazier, S., Vanhaezebrouck, I., Rebhun, R. B., Reilly, C. M. and Rodriguez, C. O. (2015), Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999–2012). Veterinary and Comparative Oncology, 13: 267–280. doi: 10.1111/vco.12042
- Issue online: 21 AUG 2015
- Version of Record online: 31 MAY 2013
- Manuscript Accepted: 29 APR 2013
- Manuscript Revised: 24 APR 2013
- Manuscript Received: 12 DEC 2012
- mast cell tumour;
- radiation therapy;
This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359 days (range, 188–2340). Median disease-free interval was 2120 days (149–2325 days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103 days; 188–2010 days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056 days; 300–2340 days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40 months.